<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202055</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-01/ET-01</org_study_id>
    <nct_id>NCT04202055</nct_id>
  </id_info>
  <brief_title>Immunologic Biomarker Profile of Cerebrospinal Fluid</brief_title>
  <acronym>BIOMOG</acronym>
  <official_title>Immunologic Biomarker Profile of Cerebrospinal Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was the describe the Immunologic biomarker profile of cerebrospinal
      fluid in multiple sclerosis patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of glial fibrillar acidic protein in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of chitinase-3-like protein 1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of neurofilament in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Interleukin-6 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Interleukin-8 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of C-X-C motif ligand (CXCL-13) in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Matrix metalloproteinase-9 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Soluble CD27 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Interleukin 10 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Interleukin 17A in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of Interleukin 1B in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of monocyte chemoattractant protein-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of soluble vascular cell adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of glial fibrillar acidic protein in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of chitinase-3-like protein 1 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of neurofilament in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Interleukin-6 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Interleukin-8 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of C-X-C motif ligand (CXCL-13) in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Matrix metalloproteinase-9 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Soluble CD27 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Interleukin 10 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Interleukin 17A in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Interleukin 1B in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of monocyte chemoattractant protein-1 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of soluble vascular cell adhesion molecule-1 in cerebrospinal fluid in each group</measure>
    <time_frame>Baseline</time_frame>
    <description>enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">165</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Neuromyelitis Optica</condition>
  <arm_group>
    <arm_group_label>Neuromyelitis optica with anti-MOG</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Neuromyelitis optica with anti-AQP4</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Seronegative patients with Neuromyelitis optica</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with recurrent-remitting multiple sclerosis</arm_group_label>
    <description>Patients with recurrent-remitting multiple sclerosis with medullary or optic involvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progressive multiple sclerosis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker analysis</intervention_name>
    <description>Detection of biomarker in cerebrospinal fluid</description>
    <arm_group_label>Neuromyelitis optica with anti-MOG</arm_group_label>
    <arm_group_label>Patients with Neuromyelitis optica with anti-AQP4</arm_group_label>
    <arm_group_label>Patients with recurrent-remitting multiple sclerosis</arm_group_label>
    <arm_group_label>Progressive multiple sclerosis patients</arm_group_label>
    <arm_group_label>Seronegative patients with Neuromyelitis optica</arm_group_label>
    <arm_group_label>Symptomatic controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Samples stored from the NOMADMUS cohort in the OFSEP collection and the NEURO collection
        from the Centre de Collections Biologiques Hospitalières
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who have had neuromyelitis ptica with anti-AQP4 antibodies, or anti- Myelin
             Oligodendrocyte Glycoprotein antibodies, or double seronegative antibodies.

          -  Neuromyelitis Optica patients have been prospectively included in the OFSEP collection

          -  Multiple sclerosis patients, isolated myelitis or optic neuritis patients, and
             symptomatic controls whose samples will come from the &quot;NEURO&quot; collection of the
             Hospital Biological Collections Center,

          -  Patients have given their free consent for use of their samples in research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Thouvenot</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

